Cargando…

Risk of Recurrent Bleeding Events in Nonvalvular Atrial Fibrillation Treated with Vitamin K Antagonists: A Clinical Practice Research Datalink Study

Background There is little evidence on how the occurrence of a bleed in individuals on vitamin K antagonists (VKAs) impacts the risk of subsequent bleeds, and thromboembolic and ischemic events. Such information would help to inform treatment decisions following bleeds. Objective To estimate the i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alikhan, Raza, Lefevre, Cinira, Menown, Ian, Lister, Steven, Bird, Alex, You, Min, Evans, David, Sammon, Cormac
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2019
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777986/ https://www.ncbi.nlm.nih.gov/pubmed/31592518 http://dx.doi.org/10.1055/s-0039-1698413

Ejemplares similares

Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study
por: Van Ganse, Eric, et al.
Publicado: (2020)

Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Under-recording of hospital bleeding events in UK primary care: a linked Clinical Practice Research Datalink and Hospital Episode Statistics study
por: McDonald, Laura, et al.
Publicado: (2018)

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding
por: Lip, Gregory Y. H., et al.
Publicado: (2021)

Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis
por: Wang, Kang-Ling, et al.
Publicado: (2015)

Special considerations for therapeutic choice of non–vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation
por: Okumura, Ken, et al.
Publicado: (2016)

Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation
por: Kinjo, Norito, et al.
Publicado: (2023)

A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Zhou, Ling-Yun, et al.
Publicado: (2018)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis
por: Xiong, Qinmei, et al.
Publicado: (2019)

Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice
por: An, JaeJin, et al.
Publicado: (2015)

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
por: Patel, Manesh R., et al.
Publicado: (2018)

Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial Fibrillation
por: Mercaldi, Catherine J., et al.
Publicado: (2012)

Short‐Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care
por: Bouillon, Kim, et al.
Publicado: (2016)

Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation
por: Souverein, Patrick C., et al.
Publicado: (2020)

Oral Anticoagulants in Very Elderly Nonvalvular Atrial Fibrillation Patients With High Bleeding Risks: ANAFIE Registry
por: Okumura, Ken, et al.
Publicado: (2022)

Analysis of Influencing Factors of Compliance with Non-Vitamin K Antagonist Oral Anticoagulant in Patients with Nonvalvular Atrial Fibrillation and Correlation with the Severity of Ischemic Stroke
por: Zhu, Li, et al.
Publicado: (2021)

Right atrium thrombosis in nonvalvular permanent atrial fibrillation
por: Bălăceanu, A.
Publicado: (2011)

Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation
por: Sen, Souvik, et al.
Publicado: (2014)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Altered profile of circulating microparticles in nonvalvular atrial fibrillation
por: Siwaponanan, Panjaree, et al.
Publicado: (2019)

Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non–Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
por: Reddy, Vivek Y., et al.
Publicado: (2018)

The Safety and Efficacy of Standard-Dose versus Low-Dose Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Left Atrial Appendage Thrombus
por: Feng, Mingjun, et al.
Publicado: (2021)

Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Collado, Fareed Moses S., et al.
Publicado: (2021)

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review
por: Milling, Truman J., et al.
Publicado: (2017)

Association Between the Change in Total Bilirubin and Risk of Bleeding Among Patients With Nonvalvular Atrial Fibrillation Taking Dabigatran
por: Xiong, Yurong, et al.
Publicado: (2020)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Mitral Regurgitation and Body Mass Index Increase the Predictability of Perioperative Bleeding in Anticoagulated Patients With Nonvalvular Atrial Fibrillation
por: Huang, Hao, et al.
Publicado: (2022)

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients
por: Lamberts, Morten, et al.
Publicado: (2017)

SAIL study of stroke, systemic embolism and bleeding outcomes with warfarin anticoagulation in non-valvular atrial fibrillation (S(4)-BOW-AF)
por: Harris, Daniel E, et al.
Publicado: (2023)

Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
por: Ferro, D., et al.
Publicado: (2007)

Nonvalvular atrial fibrillation in India—time to pause, think, and change!
por: Singh, Balbir
Publicado: (2018)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
por: Davis, Margot K., et al.
Publicado: (2021)

Massive Left Atrial Thrombi during Dabigatran Therapy for Nonvalvular Atrial Fibrillation
por: Bachvarova, Velislava, et al.
Publicado: (2017)

Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed
por: Crivera, Concetta, et al.
Publicado: (2016)

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
por: Tamayo, Sally, et al.
Publicado: (2015)

Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function
por: Pham, Phuong, et al.
Publicado: (2020)

Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists: A French Nationwide Propensity-Matched Cohort Study
por: Maura, Géric, et al.
Publicado: (2015)

Growth Differentiation Factor-15 Based ABC (Age, Biomarkers, Clinical History)-AF (Atrial Fibrillation)-Bleeding Risk Score for Elderly Patients with Nonvalvular Atrial Fibrillation
por: O, U Fan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_90fg9tc64mfqhth1656qkomusn